10.145 USD
-0.59 (-5.45%)
10.145 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 86% to CBIO. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 27.03. This target is 166.44% above the current price.
- CBIO was analyzed by 13 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about CBIO.
- In the previous month the buy percentage consensus was at a similar level.
- CBIO was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-01-21 | Guggenheim | Initiate | Buy |
| 2025-08-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-25 | Jefferies | Initiate | Buy |
| 2025-08-11 | HC Wainwright & Co. | Initiate | Buy |
| 2025-07-14 | Wedbush | Initiate | Outperform |
| 2025-06-25 | Stifel | Initiate | Buy |
| 2025-06-18 | LifeSci Capital | Initiate | Outperform |
| 2021-11-15 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2021-08-06 | Raymond James | Maintains | Outperform |
| 2021-04-29 | Raymond James | Maintains | Outperform |
| 2021-02-10 | Piper Sandler | Initiate | Overweight |
CRESCENT BIOPHARMA INC / CBIO FAQ
What do analysts expect the price target to be for CRESCENT BIOPHARMA INC (CBIO)?
13 analysts have analysed CBIO and the average price target is 27.03 USD. This implies a price increase of 166.44% is expected in the next year compared to the current price of 10.145.
What is the consensus rating for CBIO stock?
The consensus rating for CRESCENT BIOPHARMA INC (CBIO) is 86.1538 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed CRESCENT BIOPHARMA INC (CBIO)?
The number of analysts covering CRESCENT BIOPHARMA INC (CBIO) is 13.